YMAB (Y-mAbs Therapeutics Inc) Cumulative Company Assets

Official company branding of Y-mAbs Therapeutics Inc (YMAB)

Y-mAbs Therapeutics attracts leading antibody experts and immunologists, creating an agile environment to combat pediatric tumors. This chart of stock quotes demonstrates total assets, which currently stand at 130.63. Therapy safety is ensured by strict adherence to temperature controls during transport. High confidence from the medical community confirms the company's status as an ethical developer of high-precision drugs.

Y-mAbs Therapeutics Inc (YMAB) Aggregate Company Assets: for the period 07/04/2022 - 09/27/2025

Financial and market metric breakdowns for YmAbs (YMAB)

- share price and consensus valuation forecast:
Price Chart ymabs.com|YMAB - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Y-mAbs Corp|YMAB - Enterprise Value
- company book value details:
Book Value per Share Y-mAbs Therapeutics|YMAB - Company Book Value|Capitalization to Book Value Ratio ymabs.com|YMAB - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Y-mAbs Therapeutics|YMAB - Long-Term Debt to Capital|Current Liabilities to Capital Y-mAbs Corp|YMAB - Company Debts|Debt to Net Assets Ratio Y-mAbs Corp|YMAB - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Y-mAbs Therapeutics|Quick Liquidity Indicator ymabs.com
- earnings and market multiples details:
YMAB - Net Income
Basic company analysis:ymabs.com (YMAB)
Core merchandise of Y-mAbs Therapeutics, Inc.

Professional capital assesses the profile of Y-mAbs Therapeutics (YMAB) through the dynamics of its resource base. This metric, calculated inversely via ROA, measures the aggregate of assets and liabilities, where growth in assets and resources confirms the expansion of financial potential. For Y-mAbs Therapeutics (YMAB), this signifies the scaling of its network of core express logistics distribution centers. A steady increase in the base while maintaining margins guarantees the fundamental stability of the business.

Key competitors

ONC (beigene.com) - Aggregate Company Assets|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Aura Corp (AURA)|Aggregate Company Assets Candel Therapeutics Inc.|ARAY: Aggregate Asset Value|Cumulative Company Assets SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Aggregate Asset Value|Company Total Assets CTOR (Citius Oncology, Inc)|HURA - Cumulative Company Assets|TARA: Cumulative Company Assets|FATE - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Cumulative Company Assets CVM (CEL-SCI Corporation)|OSTX - Company Assets|Radiopharm Theranostics - Cumulative Company Assets|Company Balance Sheet Assets Artiva Biotherapeutics Inc.|ANL - Aggregate Company Assets|Veru Corporation (VERU) - Cumulative Company Assets|TPST: Company Total Assets|Xilio Therapeutics (XLO) - Company Total Assets|RENB (Renovaro Biosciences) - Company Total Assets|Aggregate Company Assets MURA|Aggregate Company Assets Kairos Pharma Ltd (KAPA)|Company Total Asset Base onkuretherapeutics.com|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|APLM: Cumulative Company Assets|Tharimmune Inc - Aggregate Business Assets|ADVB: Company Total Assets|Genprex Inc - Aggregate Asset Value|CLDI (Calidi Biotherapeutics Inc.) - Company Total Assets|Company Assets sunshinebiopharma.com SBFM|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX (Salarius Pharmaceuticals Inc) - Aggregate Asset Value|Company Total Assets PPBT (Purple Biotech Corp)|Company Total Assets American Oncology Network Inc AONC|BGNE - Aggregate Company Assets|Total Asset Value of Company CKPT|ELEV: Company Total Assets|Company Assets iCAD (ICAD)|Cumulative Company Assets IKNA|Company Total Assets Notable Labs Corp|Cumulative Company Assets VIRX (Viracta Therapeutics)|Aggregate Business Assets MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Company Total Asset Base Ascentage Pharma Group International (AAPGV)